Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
4-aminobutyrate aminotransferase, mitochondrial (ABAT), is a pyridoxal 5'-phosphate-dependent enzyme located in the mitochondrial matrix. It catalyzes the conversion of gamma-aminobutyric acid (GABA)—the chief inhibitory neurotransmitter in the central nervous system—into succinic semialdehyde, thereby playing a pivotal role in GABA catabolism and regulation of neuronal excitability. The enzyme is a homodimer and is essential for terminating GABAergic neurotransmission. Deficiency of ABAT leads to severe neurological impairment, while pharmacological inhibition (e.g., by vigabatrin) is a therapeutic strategy for epilepsy and occasionally other neurological conditions. This enzyme is also implicated in the pathogenesis of rare inborn errors of metabolism and may contribute to gastrointestinal disorders such as GERD via altered GABA signaling
Irreversible inhibition of GABA transaminase (by vigabatrin), leading to increased brain GABA levels and enhanced inhibitory neurotransmission
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 4-aminobutyrate aminotransferase, mitochondrial (ABAT (also GABA-T, GABA transaminase/GABA-AT, GABAT)).